Tests metformin in Veterans with prediabetes and blood vessel disease
Tests whether metformin lowers heart attack and stroke risk in prediabetic adults with heart disease.
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Albuquerque, Aurora, Baltimore, Bay Pines, Boston, Charleston, Chicago, Cincinnati, Cleveland, Columbia, Dallas, Decatur, Durham, Gainesville, Hines, Honolulu, Houston, Huntington, Iowa City, Kansas City, Lexington, Little Rock, Loma Linda, Long Beach, Memphis, Miami, Milwaukee, Minneapolis, New York, Omaha, Palo Alto, Phoenix, Portland, Richmond, Salem, Salt Lake City, San Diego, Tucson, West Haven, and West Los Angeles, United StatesSee the 40 sites
- Trial code
- Registry title
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 7,410 people, planned
- Started
- 3 Apr 2023
- Expected to end
- 28 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Metformin XR
- Placebo
- Record updated
- 17 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pre-diabetes who also have atherosclerotic disease of the heart, brain or leg arteries. It tests whether metformin lowers the risk of death, heart attack or stroke.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Pre-diabetes (HbA1c at least 5.7% (39 mmol/mol) but less than 6.5% (48 mmol/mol), or fasting glucose 100-125 mg/dL (5.6–6.9 mmol/L) on two days, or 2-hour glucose 140-199 mg/dL (7.8–11 mmol/L) after a 75 g glucose drink) plus atherosclerotic disease in the coronary, brain or leg arteries.
- Earlier treatment
- No metformin or other anti-diabetes medicine in the 12 months before joining. No systemic glucocorticoids in the 3 months before joining.
- Biomarker or test result
- Estimated glomerular filtration rate (kidney function) of at least 45 mL/min/1.73 m2.
Main reasons for not taking part
- Fasting glucose above 130 mg/dL (7.2 mmol/L), any glucose 180 mg/dL (10 mmol/L), or HbA1c 7.0% (53 mmol/mol) in the past 12 months
- Cirrhosis, active hepatitis or jaundice
- Severe anemia (hemoglobin below 10 g/dL)
- Earlier intolerance to metformin
- Pregnant, planning pregnancy or breastfeeding
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Pre-diabetes: This condition is fulfilled by HbA1c of at least 5.7%, but less than 6.5%; or two measurements of fasting plasma glucose (on separate days) of 100-125 mg/dL; or a 2-hour plasma glucose level of 140-199 mg/dL following a 75 g glucose load oral glucose tolerance test
- Established atherosclerotic cardiovascular disease: Qualifying participants must have evidence of atherosclerotic disease in at least one of the following vascular beds: coronary, cerebrovascular, or peripheral arterial circulation; Coronary artery disease is fulfilled by at least one of (1), (2), or (3):
- History of myocardial infarction at least one month prior to randomization
- History of percutaneous coronary intervention or coronary artery bypass surgery at least one month prior to randomization
- Angiographic evidence of coronary stenosis of at least 50% in at least two major epicardial coronary arteries; Cerebrovascular disease is fulfilled by at least one of criteria (1) through (4):
- Documented prior ischemic stroke (at least one month prior to randomization),
- Carotid artery stenosis 50% and history of transient ischemic attack or transient ischemic visual symptoms attributable to the identified lesion(s),
- Asymptomatic carotid stenosis of at least 70% luminal diameter,
- History of carotid revascularization (surgical or catheter-based); Peripheral arterial disease: Fulfilled by at least one of the following:
- History of aorto-iliac or peripheral artery intervention (surgical or catheter based) for limb ischemia, or amputation for limb ischemia,
- Symptoms of intermittent claudication with ankle:brachial index less than or equal to 0.85
- Renal function: Estimated glomerular filtration rate at least 45 mL/min/1.73 m2
- Informed consent has been fully executed, and participant agrees to study procedures
Who cannot take part
- Treatment with metformin or other anti-diabetic medication within 12 months of randomization. Note: In the absence of a diagnosis of diabetes, inpatient treatment with insulin or treatment with an SGLT2 inhibitor (e.g., for heart failure) or a GLP-1 receptor agonist (e.g., for obesity) is not exclusionary
- Treatment with systemic glucocorticoids within 3 months of randomization
- Current treatment with cimetidine, vandetanib, or a systemic treatment with a carbonic anhydrase inhibitor
- Prior history of intolerance to metformin
- Concurrent participation in another research study involving a randomized comparison of drug or device treatments, unless specifically excepted
- Myocardial infarction, coronary revascularization procedure, or stroke within 1 month of randomization
- Uncontrolled hypertension at screening assessment (systolic blood pressure 180 mm Hg or diastolic blood pressure 110 mm Hg
- Acute or decompensated congestive heart failure
- Impaired decision-making capacity, defined by any history of dementia or cognitive impairment
- Fasting plasma glucose greater than 130 mg/dL measured between screening and randomization visits, or any plasma glucose 180 mg/dL or HbA1c 7.0% measured within 12 months of randomization
- Total CO2 below the local laboratory lower limit of normal on most recent blood chemistry panel
- Cirrhosis, active hepatitis, or jaundice at time of randomization, or total bilirubin > 2 times upper limit of normal
- Severe anemia (hemoglobin < 10 g/dL)
- Binge or heavy alcohol consumption within 6 months of randomization
- Expected survival less than study duration
- Participants considered to be unable, unwilling, or unreliable to meet protocol requirements
- Pregnant, intent to become pregnant during the trial, or lactating
- Women of childbearing potential who are not using a highly effective method of contraception
Where in United States
- New Mexico VA Health Care System, Albuquerque, NMAlbuquerque, United StatesContact: Michelle D Ratliff, MDTaking people
- Rocky Mountain Regional VA Medical Center, Aurora, COAurora, United StatesContact: Sridharan Raghavan, MD PhDTaking people
- Rehabilitation R&D Service, Baltimore, MDBaltimore, United StatesContact: Ilias Spanakis, MDTaking people
- Bay Pines VA Healthcare System, Pay Pines, FLBay Pines, United StatesContact: Manjunath Harlapur, MDTaking people
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MABoston, United StatesContact: Scott Kinlay, MDTaking people
- Ralph H. Johnson VA Medical Center, Charleston, SCCharleston, United StatesContact: Ashley Waring, MDTaking people
- Jesse Brown VA Medical Center, Chicago, ILChicago, United StatesContact: Gregory G Schwartz, PhD MDNo longer taking part
- Cincinnati VA Medical Center, Cincinnati, OHCincinnati, United StatesContact: Gregory G Schwartz, PhD MDNo longer taking part
- Louis Stokes VA Medical Center, Cleveland, OHCleveland, United StatesContact: Laure Sayyed Kassem, MDTaking people
- Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SCColumbia, United StatesContact: Subhashini Yaturu, MDTaking people
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TXDallas, United StatesContact: Colleen Sam, MDTaking people
- Atlanta VA Medical and Rehab Center, Decatur, GADecatur, United StatesContact: Mary Rhee, MDTaking people
- Durham VA Medical Center, Durham, NCDurham, United StatesContact: Matthew Crowley, MDTaking people
- North Florida/South Georgia Veterans Health System, Gainesville, FLGainesville, United StatesContact: Carsten Schmalfuss, MDTaking people
- Edward Hines Jr. VA Hospital, Hines, ILHines, United StatesContact: Amit Dayal, MDTaking people
- VA Pacific Islands Health Care System, Honolulu, HIHonolulu, United StatesContact: Kelsey Shikuma-Lee, MDTaking people
- Michael E. DeBakey VA Medical Center, Houston, TXHouston, United StatesContact: Arunima Misra, MDTaking people
- Huntington VA Medical Center, Huntington, WVHuntington, United StatesContact: Tina Sias, MDTaking people
- Iowa City VA Health Care System, Iowa City, IAIowa City, United StatesContact: David Katz, MDTaking people
- Kansas City VA Medical Center, Kansas City, MOKansas City, United StatesContact: Mariana Garcia-Touza, MDTaking people
- Lexington VA Medical Center, Lexington, KYLexington, United StatesContact: Dennis Karounos, MDNot yet recruiting
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, ARLittle Rock, United StatesContact: Barry Uretsky, MDTaking people
- VA Loma Linda Healthcare System, Loma Linda, CALoma Linda, United StatesContact: Geir Frivold, MDTaking people
- VA Long Beach Healthcare System, Long Beach, CALong Beach, United StatesContact: Anthony Vo, MDTaking people
- Memphis VA Medical Center, Memphis, TNMemphis, United StatesContact: Richard D Childress, MDTaking people
- Miami VA Healthcare System, Miami, FLMiami, United StatesContact: Ana Palacio, MDTaking people
- Clement J. Zablocki VA Medical Center, Milwaukee, WIMilwaukee, United StatesContact: Cynthia Kay, MDTaking people
- Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United StatesContact: Selcuk Adabag, MDTaking people
- Manhattan Campus of the VA NY Harbor Healthcare System, New York, NYNew York, United StatesContact: Binita Shah, MDTaking people
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, United StatesContact: Cyrus Desouza, MDTaking people
- VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, United StatesContact: Arlina Ahluwalia, MDTaking people
- Phoenix VA Health Care System, Phoenix, AZPhoenix, United StatesContact: Peter Reaven, MDTaking people
- VA Portland Health Care System, Portland, ORPortland, United StatesContact: North Noelck, MDTaking people
- Hunter Holmes McGuire VA Medical Center, Richmond, VARichmond, United StatesContact: Edward McFalls, MDTaking people
- Salem VA Medical Center, Salem, VASalem, United StatesContact: Ali Iranmanesh, MDTaking people
- VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesContact: Charles Lui, MDTaking people
- VA San Diego Healthcare System, San Diego, CASan Diego, United StatesContact: Leda Felicio, MDTaking people
- Southern Arizona VA Health Care System, Tucson, AZTucson, United StatesContact: Punit Goel, MDTaking people
- VA Connecticut Healthcare System West Haven Campus, West Haven, CTWest Haven, United StatesContact: Brian Malm, MDTaking people
- VA Greater Los Angeles Healthcare System, West Los Angeles, CAWest Los Angeles, United StatesContact: Tannaz Moin, MDTaking people
About the trial
What the trial wants to find out
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
The 2 groups in the trial
- MetforminTreatment being tested
Participants receive initial treatment with metformin XR 500 mg 1 tablet daily, with stepwise titration to a maximum dose of 2000 mg (4 tablets) daily.
Treatment: Metformin XR
- PlaceboPlacebo, for comparison
Participants receive initial treatment with 1 tablet daily of placebo (for metformin XR), with stepwise titration to a maximum of 4 tablets daily.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)
- Plain-language title
- Tests metformin in Veterans with prediabetes and blood vessel diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 December 2025